Biosimilars Market Research Report by Indication, Product, Manufacturing, State - United States Forecast to 2027 - Cumulative Impact of COVID-19

Biosimilars Market Research Report by Indication, Product, Manufacturing, State - United States Forecast to 2027 - Cumulative Impact of COVID-19

The United States Biosimilars Market size was estimated at USD 2,455.53 million in 2021 and expected to reach USD 3,201.73 million in 2022, and is projected to grow at a CAGR 26.29% to reach USD 9,963.11 million by 2027.

Market Statistics:



The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.


Market Segmentation & Coverage:

This research report categorizes the Biosimilars to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Indication, the market was studied across Autoimmune Diseases, Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Infectious Diseases, and Oncology.

Based on Product, the market was studied across Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, and Recombinant Peptides. The Recombinant Glycosylated Proteins is further studied across Erythropoietin, Follitropin, and Monoclonal Antibodies. The Monoclonal Antibodies is further studied across Adalimumab, Infliximab, and Rituximab. The Recombinant Non-Glycosylated Proteins is further studied across Granulocyte Colony-Stimulating Factor, Insulin, Interferons, and Recombinant Human Growth Hormone. The Interferons is further studied across Interferon-Alpha and Interferon-Beta. The Recombinant Peptides is further studied across Calcitonin and Glucagon.

Based on Manufacturing, the market was studied across Contract Manufacturing and In-House Manufacturing.

Based on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:

We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Biosimilars market considering the current update on the conflict and its global response.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Biosimilars Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Biosimilars Market, including AMEGA Biotech S.A., Amgen Inc., Apotex Inc., Biosidus S.A., Bioton S.A., Innovent Biologics, Inc., JHL Biotech, Inc., LG Chem, Ltd., Merck Sharp & Dohme Corp., Mylan N.V., Pfizer Inc., and Sandoz International GmbH.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the United States Biosimilars Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Biosimilars Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Biosimilars Market?
4. What is the competitive strategic window for opportunities in the United States Biosimilars Market?
5. What are the technology trends and regulatory frameworks in the United States Biosimilars Market?
6. What is the market share of the leading vendors in the United States Biosimilars Market?
7. What modes and strategic moves are considered suitable for entering the United States Biosimilars Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19
6. Biosimilars Market, by Indication
6.1. Introduction
6.2. Autoimmune Diseases
6.3. Blood Disorders
6.4. Chronic Diseases
6.5. Growth Hormone Deficiency
6.6. Infectious Diseases
6.7. Oncology
7. Biosimilars Market, by Product
7.1. Introduction
7.2. Recombinant Glycosylated Proteins
7.3.1. Erythropoietin
7.3.2. Follitropin
7.3.3. Monoclonal Antibodies
7.3.4.1. Adalimumab
7.3.4.2. Infliximab
7.3.4.3. Rituximab
7.3. Recombinant Non-Glycosylated Proteins
7.4.1. Granulocyte Colony-Stimulating Factor
7.4.2. Insulin
7.4.3. Interferons
7.4.4.1. Interferon-Alpha
7.4.4.2. Interferon-Beta
7.4.4. Recombinant Human Growth Hormone
7.4. Recombinant Peptides
7.5.1. Calcitonin
7.5.2. Glucagon
8. Biosimilars Market, by Manufacturing
8.1. Introduction
8.2. Contract Manufacturing
8.3. In-House Manufacturing
9. California Biosimilars Market
9.1. Introduction
10. Florida Biosimilars Market
10.1. Introduction
11. Illinois Biosimilars Market
11.1. Introduction
12. New York Biosimilars Market
12.1. Introduction
13. Ohio Biosimilars Market
13.1. Introduction
14. Pennsylvania Biosimilars Market
14.1. Introduction
15. Texas Biosimilars Market
15.1. Introduction
16. Competitive Landscape
16.1. FPNV Positioning Matrix
16.1.1. Quadrants
16.1.2. Business Strategy
16.1.3. Product Satisfaction
16.2. Market Ranking Analysis, By Key Player
16.3. Market Share Analysis, By Key Player
16.4. Competitive Scenario
16.4.1. Merger & Acquisition
16.4.2. Agreement, Collaboration, & Partnership
16.4.3. New Product Launch & Enhancement
16.4.4. Investment & Funding
16.4.5. Award, Recognition, & Expansion
17. Company Usability Profiles
17.1. AMEGA Biotech S.A.
17.1.1. Business Overview
17.1.2. Key Executives
17.1.3. Product & Services
17.2. Amgen Inc.
17.2.1. Business Overview
17.2.2. Key Executives
17.2.3. Product & Services
17.3. Apotex Inc.
17.3.1. Business Overview
17.3.2. Key Executives
17.3.3. Product & Services
17.4. Biosidus S.A.
17.4.1. Business Overview
17.4.2. Key Executives
17.4.3. Product & Services
17.5. Bioton S.A.
17.5.1. Business Overview
17.5.2. Key Executives
17.5.3. Product & Services
17.6. Innovent Biologics, Inc.
17.6.1. Business Overview
17.6.2. Key Executives
17.6.3. Product & Services
17.7. JHL Biotech, Inc.
17.7.1. Business Overview
17.7.2. Key Executives
17.7.3. Product & Services
17.8. LG Chem, Ltd.
17.8.1. Business Overview
17.8.2. Key Executives
17.8.3. Product & Services
17.9. Merck Sharp & Dohme Corp.
17.9.1. Business Overview
17.9.2. Key Executives
17.9.3. Product & Services
17.10. Mylan N.V.
17.10.1. Business Overview
17.10.2. Key Executives
17.10.3. Product & Services
17.11. Pfizer Inc.
17.11.1. Business Overview
17.11.2. Key Executives
17.11.3. Product & Services
17.12. Sandoz International GmbH
17.12.1. Business Overview
17.12.2. Key Executives
17.12.3. Product & Services
18. Appendix
18.1. Discussion Guide
18.2. License & Pricing
List of Figures
FIGURE 1. UNITED STATES BIOSIMILARS MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES BIOSIMILARS MARKET SIZE, 2021 VS 2027
FIGURE 3. UNITED STATES BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 4. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 5. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 6. UNITED STATES BIOSIMILARS MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2027
FIGURE 7. UNITED STATES BIOSIMILARS MARKET DYNAMICS
FIGURE 8. UNITED STATES BIOSIMILARS MARKET SIZE, BY INDICATION, 2021 VS 2027 (%)
FIGURE 9. UNITED STATES BIOSIMILARS MARKET SIZE, BY INDICATION, 2021 VS 2027 (USD MILLION)
FIGURE 10. UNITED STATES BIOSIMILARS MARKET COMPETITIVE STRATEGIC WINDOW, BY INDICATION, 2027
FIGURE 11. UNITED STATES BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2027 (USD MILLION)
FIGURE 12. UNITED STATES BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, 2018-2027 (USD MILLION)
FIGURE 13. UNITED STATES BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, 2018-2027 (USD MILLION)
FIGURE 14. UNITED STATES BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2027 (USD MILLION)
FIGURE 15. UNITED STATES BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2027 (USD MILLION)
FIGURE 16. UNITED STATES BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2018-2027 (USD MILLION)
FIGURE 17. UNITED STATES BIOSIMILARS MARKET SIZE, BY PRODUCT, 2021 VS 2027 (%)
FIGURE 18. UNITED STATES BIOSIMILARS MARKET SIZE, BY PRODUCT, 2021 VS 2027 (USD MILLION)
FIGURE 19. UNITED STATES BIOSIMILARS MARKET COMPETITIVE STRATEGIC WINDOW, BY PRODUCT, 2027
FIGURE 20. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2027 (USD MILLION)
FIGURE 21. UNITED STATES BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, 2018-2027 (USD MILLION)
FIGURE 22. UNITED STATES BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, 2018-2027 (USD MILLION)
FIGURE 23. UNITED STATES BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2027 (USD MILLION)
FIGURE 24. UNITED STATES BIOSIMILARS MARKET SIZE, BY ADALIMUMAB, 2018-2027 (USD MILLION)
FIGURE 25. UNITED STATES BIOSIMILARS MARKET SIZE, BY INFLIXIMAB, 2018-2027 (USD MILLION)
FIGURE 26. UNITED STATES BIOSIMILARS MARKET SIZE, BY RITUXIMAB, 2018-2027 (USD MILLION)
FIGURE 27. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2027 (USD MILLION)
FIGURE 28. UNITED STATES BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR, 2018-2027 (USD MILLION)
FIGURE 29. UNITED STATES BIOSIMILARS MARKET SIZE, BY INSULIN, 2018-2027 (USD MILLION)
FIGURE 30. UNITED STATES BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2027 (USD MILLION)
FIGURE 31. UNITED STATES BIOSIMILARS MARKET SIZE, BY INTERFERON-ALPHA, 2018-2027 (USD MILLION)
FIGURE 32. UNITED STATES BIOSIMILARS MARKET SIZE, BY INTERFERON-BETA, 2018-2027 (USD MILLION)
FIGURE 33. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT HUMAN GROWTH HORMONE, 2018-2027 (USD MILLION)
FIGURE 34. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2027 (USD MILLION)
FIGURE 35. UNITED STATES BIOSIMILARS MARKET SIZE, BY CALCITONIN, 2018-2027 (USD MILLION)
FIGURE 36. UNITED STATES BIOSIMILARS MARKET SIZE, BY GLUCAGON, 2018-2027 (USD MILLION)
FIGURE 37. UNITED STATES BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2021 VS 2027 (%)
FIGURE 38. UNITED STATES BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2021 VS 2027 (USD MILLION)
FIGURE 39. UNITED STATES BIOSIMILARS MARKET COMPETITIVE STRATEGIC WINDOW, BY MANUFACTURING, 2027
FIGURE 40. UNITED STATES BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, 2018-2027 (USD MILLION)
FIGURE 41. UNITED STATES BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, 2018-2027 (USD MILLION)
FIGURE 42. CALIFORNIA BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 43. FLORIDA BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 44. ILLINOIS BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 45. NEW YORK BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 46. OHIO BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 47. PENNSYLVANIA BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 48. TEXAS BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 49. UNITED STATES BIOSIMILARS MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 50. UNITED STATES BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 51. UNITED STATES BIOSIMILARS MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2021
List of Tables
TABLE 1. UNITED STATES BIOSIMILARS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018–2021
TABLE 3. UNITED STATES BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 4. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2018-2027 (USD MILLION)
TABLE 5. UNITED STATES BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 6. UNITED STATES BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2027 (USD MILLION)
TABLE 7. UNITED STATES BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY STATE, 2018-2027 (USD MILLION)
TABLE 8. UNITED STATES BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, 2018-2027 (USD MILLION)
TABLE 9. UNITED STATES BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, BY STATE, 2018-2027 (USD MILLION)
TABLE 10. UNITED STATES BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, 2018-2027 (USD MILLION)
TABLE 11. UNITED STATES BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, BY STATE, 2018-2027 (USD MILLION)
TABLE 12. UNITED STATES BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2027 (USD MILLION)
TABLE 13. UNITED STATES BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY STATE, 2018-2027 (USD MILLION)
TABLE 14. UNITED STATES BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2027 (USD MILLION)
TABLE 15. UNITED STATES BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, BY STATE, 2018-2027 (USD MILLION)
TABLE 16. UNITED STATES BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2018-2027 (USD MILLION)
TABLE 17. UNITED STATES BIOSIMILARS MARKET SIZE, BY ONCOLOGY, BY STATE, 2018-2027 (USD MILLION)
TABLE 18. UNITED STATES BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 19. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2027 (USD MILLION)
TABLE 20. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, BY STATE, 2018-2027 (USD MILLION)
TABLE 21. UNITED STATES BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, 2018-2027 (USD MILLION)
TABLE 22. UNITED STATES BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, BY STATE, 2018-2027 (USD MILLION)
TABLE 23. UNITED STATES BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, 2018-2027 (USD MILLION)
TABLE 24. UNITED STATES BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, BY STATE, 2018-2027 (USD MILLION)
TABLE 25. UNITED STATES BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2027 (USD MILLION)
TABLE 26. UNITED STATES BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY STATE, 2018-2027 (USD MILLION)
TABLE 27. UNITED STATES BIOSIMILARS MARKET SIZE, BY ADALIMUMAB, 2018-2027 (USD MILLION)
TABLE 28. UNITED STATES BIOSIMILARS MARKET SIZE, BY ADALIMUMAB, BY STATE, 2018-2027 (USD MILLION)
TABLE 29. UNITED STATES BIOSIMILARS MARKET SIZE, BY INFLIXIMAB, 2018-2027 (USD MILLION)
TABLE 30. UNITED STATES BIOSIMILARS MARKET SIZE, BY INFLIXIMAB, BY STATE, 2018-2027 (USD MILLION)
TABLE 31. UNITED STATES BIOSIMILARS MARKET SIZE, BY RITUXIMAB, 2018-2027 (USD MILLION)
TABLE 32. UNITED STATES BIOSIMILARS MARKET SIZE, BY RITUXIMAB, BY STATE, 2018-2027 (USD MILLION)
TABLE 33. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2027 (USD MILLION)
TABLE 34. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY STATE, 2018-2027 (USD MILLION)
TABLE 35. UNITED STATES BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR, 2018-2027 (USD MILLION)
TABLE 36. UNITED STATES BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR, BY STATE, 2018-2027 (USD MILLION)
TABLE 37. UNITED STATES BIOSIMILARS MARKET SIZE, BY INSULIN, 2018-2027 (USD MILLION)
TABLE 38. UNITED STATES BIOSIMILARS MARKET SIZE, BY INSULIN, BY STATE, 2018-2027 (USD MILLION)
TABLE 39. UNITED STATES BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2027 (USD MILLION)
TABLE 40. UNITED STATES BIOSIMILARS MARKET SIZE, BY INTERFERONS, BY STATE, 2018-2027 (USD MILLION)
TABLE 41. UNITED STATES BIOSIMILARS MARKET SIZE, BY INTERFERON-ALPHA, 2018-2027 (USD MILLION)
TABLE 42. UNITED STATES BIOSIMILARS MARKET SIZE, BY INTERFERON-ALPHA, BY STATE, 2018-2027 (USD MILLION)
TABLE 43. UNITED STATES BIOSIMILARS MARKET SIZE, BY INTERFERON-BETA, 2018-2027 (USD MILLION)
TABLE 44. UNITED STATES BIOSIMILARS MARKET SIZE, BY INTERFERON-BETA, BY STATE, 2018-2027 (USD MILLION)
TABLE 45. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT HUMAN GROWTH HORMONE, 2018-2027 (USD MILLION)
TABLE 46. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT HUMAN GROWTH HORMONE, BY STATE, 2018-2027 (USD MILLION)
TABLE 47. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2027 (USD MILLION)
TABLE 48. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY STATE, 2018-2027 (USD MILLION)
TABLE 49. UNITED STATES BIOSIMILARS MARKET SIZE, BY CALCITONIN, 2018-2027 (USD MILLION)
TABLE 50. UNITED STATES BIOSIMILARS MARKET SIZE, BY CALCITONIN, BY STATE, 2018-2027 (USD MILLION)
TABLE 51. UNITED STATES BIOSIMILARS MARKET SIZE, BY GLUCAGON, 2018-2027 (USD MILLION)
TABLE 52. UNITED STATES BIOSIMILARS MARKET SIZE, BY GLUCAGON, BY STATE, 2018-2027 (USD MILLION)
TABLE 53. UNITED STATES BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2027 (USD MILLION)
TABLE 54. UNITED STATES BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, 2018-2027 (USD MILLION)
TABLE 55. UNITED STATES BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, BY STATE, 2018-2027 (USD MILLION)
TABLE 56. UNITED STATES BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, 2018-2027 (USD MILLION)
TABLE 57. UNITED STATES BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY STATE, 2018-2027 (USD MILLION)
TABLE 58. CALIFORNIA BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 59. CALIFORNIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 60. CALIFORNIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 61. CALIFORNIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2027 (USD MILLION)
TABLE 62. FLORIDA BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 63. FLORIDA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 64. FLORIDA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 65. FLORIDA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2027 (USD MILLION)
TABLE 66. ILLINOIS BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 67. ILLINOIS BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 68. ILLINOIS BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 69. ILLINOIS BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2027 (USD MILLION)
TABLE 70. NEW YORK BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 71. NEW YORK BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 72. NEW YORK BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 73. NEW YORK BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2027 (USD MILLION)
TABLE 74. OHIO BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 75. OHIO BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 76. OHIO BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 77. OHIO BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2027 (USD MILLION)
TABLE 78. PENNSYLVANIA BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 79. PENNSYLVANIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 80. PENNSYLVANIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 81. PENNSYLVANIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2027 (USD MILLION)
TABLE 82. TEXAS BIOSIMILARS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 83. TEXAS BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 84. TEXAS BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 85. TEXAS BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2027 (USD MILLION)
TABLE 86. UNITED STATES BIOSIMILARS MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 87. UNITED STATES BIOSIMILARS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 88. UNITED STATES BIOSIMILARS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 89. UNITED STATES BIOSIMILARS MARKET RANKING, BY KEY PLAYER, 2021
TABLE 90. UNITED STATES BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2021
TABLE 91. UNITED STATES BIOSIMILARS MARKET MERGER & ACQUISITION
TABLE 92. UNITED STATES BIOSIMILARS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 93. UNITED STATES BIOSIMILARS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 94. UNITED STATES BIOSIMILARS MARKET INVESTMENT & FUNDING
TABLE 95. UNITED STATES BIOSIMILARS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 96. UNITED STATES BIOSIMILARS MARKET: LICENSE & PRICING

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings